Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action

被引:38
作者
Braun, SE
Chen, KY
Blazar, BR
Orchard, PJ
Cornetta, K
机构
[1] Indiana Univ, Sch Med, Dept Med Hematol Oncol, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA
[3] Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA
[4] Walther Canc Inst, Indianapolis, IN 46208 USA
[5] Univ Minnesota, Ctr Canc, Dept Pediat, Div Bone Marrow Transplantat, Minneapolis, MN 55455 USA
关键词
D O I
10.1089/10430349950017130
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We have shown that Flk2/Flt3 ligand (Flt3L)-transduced tumor vaccine induces transferable T cell protection against a murine breast cancer cell line, but a direct comparison with the potent effector GM-CSF, the activity against preestablished tumors, and the mechanism of antitumor response in this breast cancer model are not known. We compared vaccination with C3L5 cells expressing Flt3L (C3Lt-Flt3L) and GM-CSF (C3L5-GMCSF) by injecting 1 x 10(4) cells subcutaneously into the chest wall and then, after 4 weeks, challenging the contralateral chest of tumor-free mice with parental C3L5 cells. C3L5-Flt3L and C3L5-GMCSF had reduced in vivo growth rates (25% tumor formation each) compared with 100% tumor formation of C3L5 cells expressing only neomycin phosphotransferase (C3L5-G1N). However, when tumor-free animals were challenged with parental C3L5 cells, C3L5-Flt3L vaccination was significantly better at preventing tumor growth (p < 0.05) than C3L5-GMCSF vaccination (33% of C3L5-Flt3L-vaccinated animals developed tumor compared with 77% of C3L5-GMCSF-vaccinated animals). Adoptive transfer of immunity for both vaccines was demonstrated; splenic T cells from tumor-free mice protected naive mice from parental tumor challenge. To simulate minimal disease, parental C3L5 cells at two concentrations thigh, 5 x 10(3) cells; or low, 1 x 10(3) cells) were injected into the contralateral chest wall 4 days prior to treatment with C3L5-G1N or C3L5-Flt3L. C3L5-Flt3L treatment decreased contralateral parental tumor formation thigh, 67% tumor free; low, 90% tumor free) compared with C3L5-G1N treatment thigh and low, 0% tumor free). Immunodepletion of activated natural killer cells with anti-asialo-GM(1) blocked C3L5-Flt31L- and C3L5 plus soluble Flt3L-mediated antitumor activity. Thus, Flt3L-transduced tumor cells manifest potent antitumor activity, apparently mediated, at least partially, by natural killer cells.
引用
收藏
页码:2141 / 2151
页数:11
相关论文
共 54 条
[1]  
Apte RS, 1997, INVEST OPHTH VIS SCI, V38, P1277
[2]   Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes [J].
Arca, MJ ;
Krauss, JC ;
Strome, SE ;
Cameron, MJ ;
Chang, AE .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (04) :237-245
[3]  
Arca MJ, 1996, CANCER GENE THER, V3, P39
[4]  
Armstrong CA, 1996, CANCER RES, V56, P2191
[5]  
ASHER AL, 1991, J IMMUNOL, V146, P3327
[6]   MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II(+)B7-1(+) TUMOR-CELLS ARE POTENT VACCINES FOR STIMULATING TUMOR REJECTION IN TUMOR-BEARING MICE [J].
BASKAR, S ;
GLIMCHER, L ;
NABAVI, N ;
JONES, RT ;
OSTRANDROSENBERG, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (02) :619-629
[7]   Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF interferon-gamma [J].
Bausero, MA ;
PanoskaltsisMortari, A ;
Blazar, BR ;
Katsanis, E .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (02) :113-124
[8]   Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice [J].
Brasel, K ;
McKenna, HJ ;
Charrier, K ;
Morrissey, PJ ;
Williams, DE ;
Lyman, SD .
BLOOD, 1997, 90 (09) :3781-3788
[9]  
Braun SE, 1997, EXP HEMATOL, V25, P51
[10]  
BROXMEYER HE, 1995, EXP HEMATOL, V23, P1121